Psoriasis is the most prevalent immune-mediated skin disease in adults, and affects approximately 25 million people in North American and Europe alone1. Psoriasis is a complex, multifactorial disease and the exact mechanism of psoriasis is not yet fully understood1,2. In the past, most psoriasis research was performed in a xenotransplant model, where skin from a psoriasis patient is grafted onto immunodeficient mice. Although this model is useful, these experiments are laborious, expensive, and require considerable expertise and technical skill3,4. The development of the imiquimod-induced model of psoriasis is a simple, acute, cheap model that has been used with increasing frequency to better understand the inflammatory process leading to psoriasis, as well as a high-throughput screening of potential therapeutic agents3,5.
Starting on Study Day 0 and continuing daily for the duration of the study, 75mg (mice) or 150mg (rats) of 5% imiquimod cream is applied to the shaved skin on the back.
In mice, redness and scaling significantly increase by Study Day 6; whereas visual thickening score and caliper measurements increase at day 4.
Every other day animals are scored for erythema, scaling, and skin thickening as follows:
Skin caliper measurements are also taken every other day using a Digitrix II micrometer. Biopsy punches of the skin may also be taken and weighed.
The imiquimod-induced model of psoriasis is a simple model that has been used with increasing frequency to better understand the inflammatory process leading to psoriasis, as well as a high-throughput screening of potential therapeutic agents.
For more information about IMQ-Induced Psoriasis (Mice and Rats), contact us here.